Shares of AbbVie ABBV rose 1.5% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 21.90% over the past year to $2.95, which beat the estimate of $2.83.
Revenue of $13,010,000,000 rose by 50.95% year over year, which beat the estimate of $12,760,000,000.
Outlook
The upcoming fiscal year's EPS expected to be between $12.37 and $12.57.
Details Of The Call
Date: Apr 30, 2021
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/5j8dgnqr
Recent Stock Performance
Company's 52-week high was at $113.41
Company's 52-week low was at $79.11
Price action over last quarter: Up 3.65%
Company Overview
AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
